Shaping better health
REMEDY : BNSSG referral pathways & Joint Formulary

BNSSG Adult Joint Formulary

2. Cardiovascular System Guidelines

Anticoagulation Guidance

BNSSG DOAC decision aid March 2020

BNSSG Summary of considerations when prescribing a DOAC

FAQs Warfarin to DOAC switch

Anticoagulant and antiplatelet co–prescribing information

BNSSG Anticoagulation questions and answers July 2013

Changing Anticoagulants v53

NBT DOAC counselling checklist

NICE KTT16 Anticoagulants including DOACs

DOAC Decision aid July 16

UHB Anticoagulants counselling

UK SPS: Common Questions and Answers on the Practical Use of Oral Anti-coagulants in Non-valvular atrial fibrillation

BNSSG guidance on coagulopathy, thrombosis prevention and DIC for COVID-19 positive patients

Anticoagulation Patient Information Leaflets 

Anticoagulation in AF

Apixaban- A Guide for patients with Atrial Fibrillation

Dabigatran- A guide for patients with Atrial Fibrillation

Rivaroxaban- A Guide for patients with Atrial Fibrillation

Anticoagulation in DVT

Anticoagulation choices leaflet v2 in DVT June 15 –final – for printing (rotated version)
Anticoagulation choices v2 in DVT June 15–final unrotated

 

Antiplatelet Guidance

Antiplatelet Guidelines May 17 BNSSG

 

Statin Guidance

BNSSG Management of Blood Lipid Levels (Statin Guidelines) 2020

 

Heart Failure Guidance

Primary care heart failure guidelines

 

Raynaud's Phenomenon

Due to significant disruption with the supply of a number of Nifedipine preparations, see local advice document on alternative options for the management of Raynaud's Phenomenon, available here 

Medical Management of Raynauds Phenomenon in view of Nifedipine supply changes (Nov 19).pdf